This panel indicates that the SGLT2i/GLP-1 RA combination should be considered for patients with obesity and HFpEF or at HF risk as it has been associated with greater improvement of HFpEF-related outcomes when compared with monotherapy alone. Here, GLP1R is linked to Obesity.